Investors

Press Releases

Press Releases

May 24, 2021
45% (181/405) of patients with chronic functional gastrointestinal symptoms who underwent upper endoscopy with biopsy met the diagnostic criteria for eosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD) REDWOOD CITY, Calif. , May 24, 2021 (GLOBE NEWSWIRE) -- Allakos Inc.  (the “Company”)
April 19, 2021
REDWOOD CITY, Calif. , April 19, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that Baird Radford has been appointed Chief
Displaying 1 - 10 of 11

Data Provided by Refinitiv. Minimum 15 minutes delayed.